Addex Therapeutics (ADXN) Income from Non-Controlling Interests (2019 - 2026)
Addex Therapeutics (ADXN) posted Income from Non-Controlling Interests of -$2.0 million for Q1 2026, down 28.17% sequentially from -$1.6 million in Q1 2025, and down 28.17% YoY from -$2.8 million in Q1 2025.
Addex Therapeutics (ADXN) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Income from Non-Controlling Interests for 8 years, with the latest figure at -$2.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.01 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Mar 31, 2024 | -55,814.21 |
| Sep 30, 2023 | -28,791.77 |
| Jun 30, 2023 | -151,245.87 |
| Mar 31, 2023 | -33,040.33 |
| Sep 30, 2022 | 137,608.04 |
| Jun 30, 2022 | 497,505.36 |
| Mar 31, 2022 | 720,983.63 |
| Sep 30, 2021 | -3.83 Mn |
| Jun 30, 2021 | -5.00 Mn |
| Mar 31, 2021 | -2.78 Mn |
| Sep 30, 2020 | -164,484.43 |
| Jun 30, 2020 | -236,427.04 |
| Sep 30, 2019 | -368,805.92 |